Search Result

Results for "

Corrector

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (4) Autophagy (6) Bacterial (1) Biochemical Assay Reagents (1) CFTR (21) Factor Xa (2) HMG-CoA Reductase (HMGCR) (2) Isotope-Labeled Compounds (3) MALT1 (1) Mitochondrial Metabolism (2) Phosphatase (1) Potassium Channel (2)
By Research Areas:	Cancer (9) Cardiovascular Disease (6) Endocrinology (8) Inflammation/Immunology (15) Metabolic Disease (7) Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-125381

*CFTR corrector* 2** 1 Publications Verification	CFTR Autophagy	Inflammation/Immunology Cancer
CFTR corrector 2 is a *cystic fibrosis transmembrane conductance corrector* (CFTR)**, extracted from patent US20140274933 .

HY-135279

*CFTR corrector* 4**	CFTR	Inflammation/Immunology
CFTR corrector 4 (Compound 13), an active (R,R)-form enantiomer, is a highly potent and orally active cystic fibrosis transmembrane conductance regulator (CFTR) corrector. CFTR corrector 4 can increase CFTR levels at the cell surface and have the potential for treatment of cystic fibrosis .

HY-136939

*CFTR corrector* 6**	CFTR	Metabolic Disease Inflammation/Immunology
CFTR corrector 6 is a potent potentiator of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). CFTR corrector 6 has the potential for cystic fibrosis (CF) and other CFTR associated disorders research .

HY-153133

CFTR corrector 11

CFTR Others

CFTR corrector 11 (compound 133) is a CFTR corrector .

*CFTR corrector* 11**	CFTR	Others
CFTR corrector 11 (compound 133) is a CFTR corrector .

HY-155742

*CFTR corrector* 12**	CFTR	Others
CFTR corrector 12 (compound 17C) is a bithiazole derivative, serving as CFTR corrector. CFTR corrector 12 has the ability to correct some folding defective mutants of the channel responsible for the control of chloride transport across the plasma membrane. CFTR corrector 12 recovers the α-sarcoglycan (α-SG) content in mutant cells .

HY-147315

*CFTR corrector* 9**	CFTR	Others
CFTR corrector 9 (compound 42) is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. CFTR corrector 9 can be used for researching cystic fibrosis (CF) and other CFTR associated disorders .

HY-147249

CFTR corrector 8

CFTR Inflammation/Immunology

CFTR corrector 8 is a potent CFTR modulator. CFTR can be used in the research of cystic fibrosis .
HY-158002

IDOR-4

CFTR Inflammation/Immunology

IDOR-4 is a type IV CFTR corrector. IDOR-4 restores F508del-CFTR trafficking to the cell surface .

*CFTR corrector* 8**	CFTR	Inflammation/Immunology
CFTR corrector 8 is a potent CFTR modulator. CFTR can be used in the research of cystic fibrosis .

IDOR-4	CFTR	Inflammation/Immunology
IDOR-4 is a type IV CFTR corrector. IDOR-4 restores F508del-CFTR trafficking to the cell surface .

HY-15448A

(Rac)-Tezacaftor (Rac)-VX-661	CFTR	Inflammation/Immunology
(Rac)-Tezacaftor ((Rac)-VX-661) is a racemate of Tezacaftor (HY-15448). Tezacaftor is a F508del CFTR corrector. (Rac)-Tezacaftor can be used for the research of cystic fibrosis .

HY-109187

Posenacaftor PTI-801	CFTR	Inflammation/Immunology
Posenacaftor (PTI-801) is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor is used for the research of cystic fibrosis (CF) .

HY-109187B

(R)-Posenacaftor sodium (R)-PTI-801 sodium	CFTR	Inflammation/Immunology
(R)-Posenacaftor (R)-PTI-801) sodium is the R enantiomer of Posenacaftor. Posenacaftor is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor is used for the research of cystic fibrosis (CF) .

HY-126394B

Bamocaftor potassium VX-659 potassium	CFTR	Endocrinology
Bamocaftor potassium is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore F508del-CFTR protein function. Bamocaftor potassium can be used combine with Tezacaftor (HY-15448) and Ivacaftor (HY-13017) in cystic fibrosis research .

HY-126394

Bamocaftor VX-659	CFTR	Endocrinology
Bamocaftor (VX-659) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore F508del-CFTR protein function. Bamocaftor can be used combine with Tezacaftor (HY-15448) and Ivacaftor (HY-13017) in cystic fibrosis research .

HY-13262

Lumacaftor Maximum Cited Publications 12 Publications Verification VX-809; VRT 826809	CFTR Autophagy	Inflammation/Immunology
Lumacaftor (VX-809; VRT 826809) is a CFTR modulator that corrects the folding and trafficking of CFTR protein.

HY-113821

1-Naphthyl phosphate potassium salt	Phosphatase	Others
1-Naphthyl phosphate potassium salt is a non-specific phosphatase inhibitor. 1-Naphthyl phosphate potassium salt decreases the splice-correcting effect .

HY-147149

BPN-15477	Others	Neurological Disease
BPN-15477 is a potent SMC (splicing modulator compound) that restores correct splicing of ELP1 (Elongator complex protein 1) exon 20. BPN-15477 corrects splicing of the ELP1 transcript, significantly increases the level of functional protein in vivo in all tissues, including brain. BPN-15477 can be used for frontotemporal dementia research .

HY-146056

Anabolic agent-1	Others	Others
Compounds, as a new type of bone morphogenetic protein-2 up regulator, can not only correct the bone loss in patients, but also have a wide range of clinical applicability.

HY-133013

GLPG-3221	CFTR	Inflammation/Immunology
GLPG-3221 is a potent, orally active corrector of CFTR (cystic fibrosis transmembrane conductance regulator), with an EC₅₀ of 105 nM. GLPG-3221 can be uesd for the treatment of cystic fibrosis .

HY-109187A

Posenacaftor sodium 1 Publications Verification PTI-801 sodium	CFTR	Inflammation/Immunology
Posenacaftor (PTI-801) sodium is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor sodium is used for the research of cystic fibrosis (CF) .

HY-111111

Galicaftor 1 Publications Verification ABBV-2222; GLPG-2222	CFTR	Inflammation/Immunology
Galicaftor (ABBV-2222; GLPG-2222) is a potent and orally active cystic fibrosis transmembrane conductance regulator (CFTR) corrector. Galicaftor can be used for cystic fibrosis research .

HY-15448S

Tezacaftor-d4 VX-661-d₄	CFTR Autophagy	Cancer
Tezacaftor-d4 (VX-661-d4) is the deuterium-labeled Tezacaftor (HY-15448), a F508del CFTR corrector. Tezacaftor helps CFTR protein reach the cell surface .

HY-15448

Tezacaftor 5+ Cited Publications VX-661	CFTR	Cancer
Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .

HY-124758

SH-BC-893	Mitochondrial Metabolism	Metabolic Disease Cancer
SH-BC-893 is an orally active anti-neoplastic sphingolipid analog. SH-BC-893 also protects from ceramide-induced mitochondrial dysfunction and corrects diet-induced obesity. SH-BC-893 can be used for the research of cancer and obesity .

HY-19970

KM11060 2 Publications Verification	CFTR Autophagy	Endocrinology
KM11060 is a corrector of the F508 deletion (F508del)-cystic fibrosis transmembrane conductance regulator (CFTR) trafficking defect. KM11060 can be used for the research of F508del-CFTR processing defect and development of cystic fibrosis research .

HY-135869

Mito-apocynin (C11) 2 Publications Verification	Mitochondrial Metabolism	Neurological Disease
Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP ⁺ cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function .

HY-N7384

Vitamin B15 Pangamic Acid	Others	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Vitamin B15 (Pangamic Acid) is a natural, ubiquitously in plant seeds substance and can used be as an agent stimulating cellular respiration. Vitamin B15 contains D-gluconodimethyl amino acetic acid. Vitamin B15 is also a immune-correcting agent . Vitamin B15 can be used for wide range of diseases.

HY-N7384A

Vitamin B15 hemicalcium Pangamic Acid hemicalcium	Others	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Vitamin B15 (Pangamic Acid) hemicalcium is a natural, ubiquitously in plant seeds substance and can used be as an agent stimulating cellular respiration. Vitamin B15 hemicalcium contains D-gluconodimethyl amino acetic acid. Vitamin B15 hemicalcium is also a immune-correcting agent . Vitamin B15 hemicalcium can be used for wide range of diseases.

HY-17504AS

Rosuvastatin-d3 ZD 4522 d₃	Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel	Cardiovascular Disease Metabolic Disease
Rosuvastatin-d₃ is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2].

HY-153480

ARC19499 BAX499	Factor Xa	Others
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-153480A

ARC19499 sodium BAX499 sodium	Factor Xa	Others
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-17504A

Rosuvastatin ZD 4522	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-110174

NAB2	Others	Neurological Disease
NAB2 is a neuron-protective agent. NAB2 strongly and selectively protects diverse cell types from α-syn toxicity. NAB2 promots endosomal transport events dependent on the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 identifies a agentgable node in the biology of α-syn that can correct multiple aspects of its underlying pathology, including dysfunctional endosomal and endoplasmic reticulum-to-Golgi vesicle trafficking .

HY-103369

PG01	CFTR	Endocrinology
PG01 is a potent CFTR Cl ^- channel potentiator. PG01 can correct gating defects of CFTR mutants, is effective on b>E193K, G970R and G551D (CFTR mutants) with K_d values of 0.22 μM, 0.45 μM and 1.94 μM, respectively. PG01 is also effective on ΔF508 (K_a of 0.3 μM). PG01 increases ΔF508-CFTR Cl ^- current after adding Forskolin .

HY-143423A

(S)-MALT1-IN-5	MALT1	Inflammation/Immunology Cancer
(S)-MALT1-IN-5 is a potent inhibitor of MALT1 protease. (S)-MALT1-IN-5 inhibits the activity of MALT1 is expected to be able to correct the enhancement of MALT1 activity due to abnormality of T cell receptor signal or B cell receptor signal, and cancer or inflammatory disease caused by MALT1 activity is expected. (S)-MALT1-IN-5 has the potential for the research of MALT1-related diseases (extracted from patent WO2020111087A1, compound 1) .

HY-15746

Dobutamine hydrochloride 3 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion .

HY-15746A

Dobutamine
Dobutamine is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine can increase cardiac output and correct hypoperfusion .

HY-15746B

Dobutamine tartrate	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Dobutamine tartrate is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine tartrate is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine tartrate can increase cardiac output and correct hypoperfusion .

HY-15746S1

(rac)-Dobutamine-d6 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease Endocrinology
(rac)-Dobutamine-d₆ (hydrochloride) is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion[1][2][3][4].

HY-15746S

(rac)-Dobutamine-d4 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease Endocrinology
(rac)-Dobutamine-d₄ (hydrochloride) is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion[1][2][3][4].

HY-120973

Butaprost free acid	Biochemical Assay Reagents	Others
(R)-Butaprost (free acid). Butaprost is a structural analog of prostaglandin E2 (PGE2) with good selectivity for the EP2 receptor subtype. Butaprost is frequently used pharmacologically to define the expression profile of EP receptors in various human and animal tissues and cells. Gardiner caused serious confusion about the structure of butaprost in 1986 when he reported that the epimer of butaprost showing this selective activity was the C-16 (R)-epimer ( See reference 2 and notes). To increase the binding affinity of (R)-butaprost to prostaglandin receptors, we removed the methyl ester of (R)-butaprost and recreated the native C-1 carboxylic acid. Prostaglandin free acids typically bind their cognate receptors with 10 to 100-fold higher affinity than the corresponding ester derivatives. The pharmacology of (R)-butaprost has not been carefully studied, but it is generally considered to be the less active C-16 epimer. (Note: In the 1986 Gardiner paper in the British Journal of Pharmacology, butaprost appears on page 46 under the designation TR 4979. The structure drawn is incorrect because the authors use and refer to the more active C - The 16 epimer, which is actually 16(S). The structure on page 46 shows the structure as 16(R). It was not until the late 1990s that careful studies in the United States and Japan correctly determined the actual structure of C-16 The type is 16(S) in a compound called butaprost.)

Apoptosis Compound Library	2211 compounds
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease. MCE designs a unique collection of 2211 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

Butaprost free acid	Biochemical Assay Reagents
(R)-Butaprost (free acid). Butaprost is a structural analog of prostaglandin E2 (PGE2) with good selectivity for the EP2 receptor subtype. Butaprost is frequently used pharmacologically to define the expression profile of EP receptors in various human and animal tissues and cells. Gardiner caused serious confusion about the structure of butaprost in 1986 when he reported that the epimer of butaprost showing this selective activity was the C-16 (R)-epimer ( See reference 2 and notes). To increase the binding affinity of (R)-butaprost to prostaglandin receptors, we removed the methyl ester of (R)-butaprost and recreated the native C-1 carboxylic acid. Prostaglandin free acids typically bind their cognate receptors with 10 to 100-fold higher affinity than the corresponding ester derivatives. The pharmacology of (R)-butaprost has not been carefully studied, but it is generally considered to be the less active C-16 epimer. (Note: In the 1986 Gardiner paper in the British Journal of Pharmacology, butaprost appears on page 46 under the designation TR 4979. The structure drawn is incorrect because the authors use and refer to the more active C - The 16 epimer, which is actually 16(S). The structure on page 46 shows the structure as 16(R). It was not until the late 1990s that careful studies in the United States and Japan correctly determined the actual structure of C-16 The type is 16(S) in a compound called butaprost.)

Proinsulin C-peptide (human)	Peptides	Metabolic Disease
Proinsulin C-peptide (human) is a 31-amino-acid peptide that links the A and B chains of proinsulin, ensuring its correct folding, which is biologically active and modulates cellular function .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7384

Vitamin B15 Pangamic Acid	Structural Classification other families Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Plants Inflammation/Immunology Disease Research Fields	Others
Vitamin B15 (Pangamic Acid) is a natural, ubiquitously in plant seeds substance and can used be as an agent stimulating cellular respiration. Vitamin B15 contains D-gluconodimethyl amino acetic acid. Vitamin B15 is also a immune-correcting agent . Vitamin B15 can be used for wide range of diseases.

Cat. No.	Product Name	Chemical Structure

HY-15448S

Tezacaftor-d4

Tezacaftor-d4 (VX-661-d4) is the deuterium-labeled Tezacaftor (HY-15448), a F508del CFTR corrector. Tezacaftor helps CFTR protein reach the cell surface .

HY-17504AS

Rosuvastatin-d3
Rosuvastatin-d₃ is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2].

HY-15746S1

(rac)-Dobutamine-d6 hydrochloride

(rac)-Dobutamine-d₆ (hydrochloride) is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion[1][2][3][4].

HY-15746S

(rac)-Dobutamine-d4 hydrochloride

(rac)-Dobutamine-d₄ (hydrochloride) is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion[1][2][3][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks